Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Stromal Vascular Fraction for Treatment of Xerostomia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03061110
Recruitment Status : Withdrawn (Internal funding not awarded.)
First Posted : February 23, 2017
Last Update Posted : April 30, 2018
Sponsor:
Information provided by (Responsible Party):
Stephen Ray, MD, Midwestern Regional Medical Center

Tracking Information
First Submitted Date  ICMJE February 17, 2017
First Posted Date  ICMJE February 23, 2017
Last Update Posted Date April 30, 2018
Estimated Study Start Date  ICMJE November 1, 2018
Estimated Primary Completion Date December 28, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 21, 2017)
Acute Safety Profile (Reported Adverse Events graded according to CTCAE guidelines) [ Time Frame: 72 hours ]
Reported Adverse Events graded according to CTCAE guidelines will be recorded starting at or after the time of injection and at or before 72 hours post injection.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 21, 2017)
  • Chronic Safety Profile (Reported Adverse Events graded according to Common Terminology Criteria for Adverse Events (CTCAE) guidelines) [ Time Frame: Months 3, 6 and 12 after Day 0 (date of injection) ]
    Reported Adverse Events graded according to Common Terminology Criteria for Adverse Events (CTCAE) guidelines will be recorded starting on Day 0 (day of SVF injection) and ending at 12 months.
  • Unstimulated Saliva Production [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Rate of saliva production over a 5-minute period. (g/minute)
  • Stimulated Saliva Production [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Rate of saliva production while chewing gum over a 5-minute period. (g/minute)
  • University of Rotterdam Hospital Xerostomia Questionnaire- "How severe is your dry mouth problem?" [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Mean score calculated from patient-reported survey (Likert Scale; 1 = Normal; 2 = somewhat more complaints than before radiation therapy; 3 = considerable more complaints than before radiation therapy; and 4 = Permanent complaints of a very dry mouth)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Under which circumstances does the dry mouth problem occur? (In the open air) [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Incidence of each indication calculated from categorical patient-reported survey (Yes, No, Not Applicable)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Under which circumstances does the dry mouth problem occur? (In the open air in case of wind and cold) [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Incidence of each indication calculated from categorical patient-reported survey (Yes, No, Not Applicable)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Under which circumstances does the dry mouth problem occur? (In air-conditioned spaces) [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Incidence of each indication calculated from categorical patient-reported survey (Yes, No, Not Applicable)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Under which circumstances does the dry mouth problem occur? (Especially dry mouth during daytime) [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Incidence of each indication calculated from categorical patient-reported survey (Yes, No, Not Applicable)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Under which circumstances does the dry mouth problem occur? (Especially dry mouth at nighttime) [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Incidence of each indication calculated from categorical patient-reported survey (Yes, No, Not Applicable)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Under which circumstances does the dry mouth problem occur? (Always dry mouth night and day) [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Incidence of each indication calculated from categorical patient-reported survey (Yes, No, Not Applicable)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Under which circumstances does the dry mouth problem occur? (Especially bother of the dry mouth during meals) [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Incidence of each indication calculated from categorical patient-reported survey (Yes, No, Not Applicable)
  • University of Rotterdam Hospital Xerostomia Questionnaire- "How often do you wake up at night because of a dry mouth?" [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Number of events as reported by patient (Number)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "How would you describe the quality of your saliva?" [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Mean score calculated from patient-reported survey (Likert Scale; 1 = Normal, watery fluid; 2 = Normal watery but too little volume; 3 = Sticky saliva; and 4 = No saliva at all)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Do you have difficulties with speech because of the dry mouth?" [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Mean score calculated from patient-reported survey (Likert Scale; 1 = No problems; unchanged with respect to situation before radiation therapy; 2 = Occasionally some difficulty with speech; 3 = Frequently speech problems; 4 = always difficulties with speech; and 5= always major speech problems)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Do you need to sip water to facilitate speech?" [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Mean score calculated from patient-reported survey (Likert Scale; 1 = Never; 2 = Occasionally; 3 = Frequently; 4 = Always; and 5= Even have to interrupt speaking to take a sip of water)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Is swallowing changed because of the dry mouth problem?" [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Mean score calculated from patient-reported survey (Likert Scale; 1 = No problems; unchanged with respect to situation before radiation therapy; 2 = Occasionally some difficulty with swallowing; 3 = Frequently problems with swallowing; 4 = Always swallowing difficulties; and 5 = Swallowing is seriously impaired because of the dry mouth problem)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Has the dry mouth a negative influence on chewing?" [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Mean score calculated from patient-reported survey (Likert Scale; 1 = No change in chewing capability; 2 = Some difficulty with chewing; 3 = Frequently difficulties with chewing; 4 = Always difficulties with chewing; 5 = Chewing is seriously hampered because of the dry mouth problem)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Do you need to sip water to facilitate eating?" [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Mean score calculated from patient-reported survey (Likert Scale; 1 = No never; 2 = Sometimes, depending on the quality of the food; 3 = Frequently; more often than before radiation therapy; and 4 = Always need to take a sip of water/ fluid with every bite of food)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Did you change your feeding habits?" [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Mean score calculated from patient-reported survey (Likert Scale; 1 = No change; 2 = Minor changes, such as avoiding some products; 3 = Can eat only mashed food; 4 = Can eat only liquid food; and 5= Tube feeding)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Do you have painful, dry, or crusted lips?" [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Mean score calculated from patient-reported survey (Likert Scale; 1 = Never; 2 = Sometimes, depending on the weather and environmental circumstances; 3 = Frequently; and 4 = Always, day and night)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Do you need to carry a bottle of fluid with you when leaving home?" [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Mean score calculated from patient-reported survey (Likert Scale; 1 = Never 2 = Occasionally; 3 = Frequently; 4 = Very often; and 5 = Always)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Do you have a sore or painful mouth?" [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Mean score calculated from patient-reported survey (Likert Scale; 1 = Never 2 = Occasionally; 3 = Frequently; 4 = Very often; and 5 = Always)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Did your taste change?" [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Mean score calculated from patient-reported survey (Likert Scale; 1 = No change; normal taste sensation; 2 = Some reduction in taste discrimination and sensation; 3 = Considerable change in taste; 4 = No taste sensation at all; and 5 = Always a bad taste in the mouth)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Do you often have an infected oral mucosa or irritated gums?" [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Incidence of each indication calculated from categorical patient-reported survey (Yes, No, Not Applicable)
  • University of Rotterdam Hospital Xerostomia Questionnaire - "Did your teeth deteriorate after radiation therapy?" [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Mean score calculated from patient-reported survey (Likert Scale; 1 = never; 2 = Occasionally; 3 = Frequently; and 4 = Very often)
  • University of Rotterdam Hospital Xerostomia Questionnaire - Overall Xerostomia Index [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Overall Xerostomia Index is calculated from the first three questions of the Questionnaire [I = (Q1 x 15.8) + (Q2 x 8.5) + (Q3 x 5.9) - 33.2; where Qn = score of that question.]
  • University of Michigan Xerostomia-Related Quality of Life Scale - Physical Functioning [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Mean score calculated from patient-reported survey (Likert Scale; 0=Best Functioning to 4=Worst Functioning)
  • University of Michigan Xerostomia-Related Quality of Life Scale - Pain/Discomfort [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Mean score calculated from patient-reported survey (Likert Scale; 0=No Pain to 4=Worst Pain)
  • University of Michigan Xerostomia-Related Quality of Life Scale - Personal/Psychological Functioning [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Mean score calculated from patient-reported survey (Likert Scale; 0=Best Functioning to 4=Worst Functioning)
  • University of Michigan Xerostomia-Related Quality of Life Scale - Social Functioning [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Mean score between Baseline and 3 months calculated from patient-reported survey (Likert Scale; 0=Best Functioning to 4=Worst Functioning)
  • Late Effects Normal Tissue-Subjective Objective Management Analytica (LENT-SOMA) survey [ Time Frame: Assessed at Baseline and 3 months, 6 months and 12 months after Baseline ]
    Mean score calculated from patient-reported survey (Likert Scale; 1=Best Functioning to 4=Worst Functioning)
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Stromal Vascular Fraction for Treatment of Xerostomia
Official Title  ICMJE Evaluation of the Use of the Tissue Genesis® Icellator Cell Isolation System® ("Icellator") Autologous Adipose Stromal Vascular Fraction Cells as a Treatment for Post-Irradiated Induced Xerostomia in Head and Neck Cancer Patients
Brief Summary Prospective, single center, double armed, randomized treatment with observation only (standard of care) control group. Subjects receiving study treatment will have 6 months of study follow-up. Stromal vascular fraction (SVF), an adipose-derived tissue preparation, will be injected into salivary glands to determine safety and efficacy to restore saliva production in head and neck cancer patients with chronic xerostomia resulting from radiation therapy.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Subjects will be randomly assigned to usual care (palliation of symptoms) or injection of stromal vascular fraction.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Xerostomia Due to Radiotherapy (Disorder)
Intervention  ICMJE
  • Biological: Stromal Vascular Fraction
    Stromal Vascular Fraction will be produced from the subject's own adipose tissue by the Tissue Genesis Icellator device.
    Other Name: Adipose-Derived Stem Cells
  • Other: Usual Care
    Usual care will include over-the-counter and prescription methods to treat xerostomia.
    Other Name: Standard of Care
Study Arms  ICMJE
  • Active Comparator: Usual Care
    Subjects in the Usual Care arm will receive typical therapies to manage the symptoms of dry mouth including but not limited to: chewing gum, sucking sugar-free candy, sipping water, mouth rinses and over-the-counter artificial saliva preparations.
    Intervention: Other: Usual Care
  • Experimental: Stromal Vascular Fraction
    Subjects in the Stromal Vascular Fraction arm will receive single injections into each of the six (6) peri-oral salivary glands (parotid, submandibular, sublingual).
    Intervention: Biological: Stromal Vascular Fraction
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Withdrawn
Actual Enrollment  ICMJE
 (submitted: April 26, 2018)
0
Original Estimated Enrollment  ICMJE
 (submitted: February 21, 2017)
30
Estimated Study Completion Date  ICMJE December 31, 2020
Estimated Primary Completion Date December 28, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male and Female subjects are both eligible
  • Subjects must be 21 years of age or older
  • History of treated Head and Neck Cancer, no evidence of active cancer at the time of the study
  • Original tumor not located adjacent to the parotid or sub-mandibular glands
  • Diagnosis of radiation-induced xerostomia
  • study is fully explained
  • Females of child bearing potential agree to use acceptable methods of contraception through 6 month study follow-up.
  • No current malignancy or history of previous malignancy within the last five years, other than the head and neck cancer, with the exception of adequately treated non-abdominal, non-melanoma cutaneous carcinoma (basal cell or squamous cell carcinoma of the skin)
  • Willing to undergo a minor surgical procedure (small-volume liposuction, totaling approximately 60-120cc) and a single treatment of an injection of approximately 30ml of autologous Stromal Vascular Fraction taking approximately 10 minutes
  • Abdominal area amenable to liposuction of at least 60-120cc of adipose tissue based on Investigator(s) examination
  • Willing to be available for all baseline, treatment and follow-up examinations required by protocol
  • Willing to forego participation in any other study throughout the duration of this study unless receiving prior approval by Investigator

Exclusion Criteria:

  • Patients taking immunosuppressive therapy in the prior 3 months
  • Autoimmune disorders
  • Patients who are pregnant or currently breast-feeding children
  • Patients participating in a study of an experimental drug or medical device within 60 days of study entry
  • Uncontrolled hypertension
  • Reported unstable cardiovascular disease (e.g., unstable angina, myocardial infarction within past 6 months, cardiac failure or life-threatening arrhythmia, congestive heart failure) or symptomatic postural hypotension within 6 months before screening
  • Hemoglobin A1c > 8% within 8 weeks prior to study treatment
  • Current use of steroids or immunosuppressant therapies
  • Any other condition, which, in the opinion of the Investigator, would contraindicate treatment, affect compliance, interfere with study evaluations, limit study participation, or confound the interpretation of study results
  • History of Sjogren's Syndrome or related autoimmune disease.
  • Taking medication for which xerostomia is a known major side effect
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 21 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03061110
Other Study ID Numbers  ICMJE MZ2017003
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Stephen Ray, MD, Midwestern Regional Medical Center
Study Sponsor  ICMJE Midwestern Regional Medical Center
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Stephen Ray, MD Midwestern Regional Medical Center
PRS Account Midwestern Regional Medical Center
Verification Date April 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP